Skip to Main Content

++

Section 14: Hematologic Disorders

++
++
++

The genetic inheritance pattern for hemophilia is:

++
++
++

A. Autosomal dominant

++
++

B. Autosomal recessive

++
++

C. X-linked

++
++

D. Genetic polymorphism

+
+

The answer is C.

++
++
++

The factor deficit in hemophilia B is:

++
++
++

A. Factor II

++
++

B. Factor VII

++
++

C. Factor VIII

++
++

D. Factor IX

+
+

The answer is D.

++
++
++

Which of the following is not considered a goal of Hemophilia therapy?

++
++
++

A. Prevent bleeding episodes

++
++

B. Prevent long term complications

++
++

C. Eradicate inhibitors

++
++

D. Arrest bleeding if it occurs

+
+

The answer is C.

++
++
++

Patients with severe hemophilia have ______% factor activity level.

++
++
++

A. <1%

++
++

B. 1-4%

++
++

C. 3-5%

++
++

D. >5%

+
+

The answer is A.

++
++
++

The first-line therapeutic approach to treating an active bleed in a patient with severe hemophilia without inhibitors is:

++
++
++

A. Plasma derived factor replacement

++
++

B. Recombinant factor replacement

++
++

C. Activated prothrombin complex concentrates (aPCCs)

++
++

D. Desmopressin

++
++

E. Anti-thrombolytic

+
+

The answer is B.

++
++
++

Which is a true statement regarding prophylaxis therapy for hemophilia?

++
++
++

A. Not recommended by any national organization

++
++

B. Recommended approach but optimal dosing and schedule is not well defined

++
++

C. Proven cost effective

++
++

D. Patient compliance is not a factor in overall outcome

+
+

The answer is B.

++
++
++

The most impactful therapeutic complication of therapy for hemophilia patients is:

++
++
++

A. Infection

++
++

B. Cost

++
++

C. Inhibitor formation

++
++...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.